KMTS reports Q4 revenue $35.4M (+66%), gross margin 68.5%. Guides FY2027 to $137M, expects 70%+ margins. Shares up 8% after-hours.
KESTRA MEDICAL TECHNOLOGIES, LTD. currently carries an Alpha Score of n/a, giving AlphaScala's model a neutral read on the setup.
Kestra Medical Technologies (KMTS) posted fourth-quarter revenue of $35.4 million, up 66% from a year earlier. The company's wearable cardioverter defibrillator (WCD) gained share in the hospital channel, management said on the earnings call.
Gross margin for the quarter reached 68.5%, up from 63.9% in the prior-year period. The company guided fiscal 2027 revenue to $137 million, representing roughly 30% growth from fiscal 2026's $105.2 million. Management expects gross margins to hit 70% or higher over the next few years as production scales and the mix shifts toward higher-margin hospital contracts.
Kestra ended the quarter with $274 million in cash after its October initial public offering. The company added 125 new hospital accounts in fiscal 2026, bringing the total to 1,254. It ended the year with about 11,000 active patients on its monitoring platform.
Kestra's WCD devices compete with Zoll's LifeVest in the cardiac monitoring market. The stock rose 8% in after-hours trading following the release.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.